Related Experiment Video
Updated: Jun 13, 2026
05:47
Repetitive Transcranial Magnetic Stimulation to the Unilateral Hemisphere of Rat Brain
Published on: October 22, 2016
Repetitive transcranial magnetic stimulation for ALS
M Dileone1, P Profice, F Pilato
1Department of Neuroscience, Institute of Neurology, Università Cattolica, L.go A. Gemelli 8, 00168 Rome, Italy. mdileone1@tin.it
CNS & Neurological Disorders Drug Targets
|April 22, 2010
Summary
Repetitive transcranial magnetic stimulation (rTMS) shows potential for slowing amyotrophic lateral sclerosis (ALS) progression by reducing excitotoxicity. However, current evidence indicates limited long-term benefits, warranting further research into optimal stimulation protocols.
Area of Science:
- Neuroscience
- Neurology
- Neurodegenerative Diseases
Background:
- Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease impacting motor neurons.
- Glutamate excitotoxicity is a proposed mechanism driving motor neuron death in ALS.
- Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique.
Purpose of the Study:
- To investigate the potential therapeutic effects of rTMS on ALS progression.
- To explore the mechanisms by which rTMS might influence motor neuron survival, including excitotoxicity and neurotrophic factors.
- To evaluate the current evidence regarding the efficacy of rTMS in ALS treatment.
Main Methods:
- Review of published studies on rTMS application in amyotrophic lateral sclerosis (ALS).
- Analysis of preliminary data suggesting rTMS may slow disease progression.
- Examination of proposed mechanisms, such as modulation of glutamate excitotoxicity and brain-derived neurotrophic factor (BDNF).
Main Results:
- Preliminary studies indicated that low-frequency rTMS might slightly slow ALS progression, potentially by reducing cortical excitability and glutamate-driven excitotoxicity.
- rTMS may also influence motor neuron survival by modulating brain-derived neurotrophic factor (BDNF) levels.
- Recent studies report a lack of significant long-term benefits of rTMS on neurological decline in ALS patients.
Conclusions:
- While initial findings were promising, current evidence does not support significant long-term efficacy of rTMS for ALS.
- Further research is needed to determine optimal rTMS protocols (technique, duration, frequency) for potential therapeutic benefit, especially in early disease stages.
